Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI

A randomized, open-label, multiple-center, parallel group study to compare the platelet inhibition with VerifyNow assay of ticagrelor versus clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Inclusion Criteria:

• Provision of signed and dated informed consent before initiation of any study-related procedures
• Male or female patients aged 18 years or older
• Documented acute coronary syndrome and troponin negative and undergoing Ad Hoc percutaneous coronary intervention (PCI)
• Females must be post menopausal or surgically sterile
• Taking aspirin as an anti-platelet medication

Exclusion Criteria:

• Use of any thienopyridine or ticagrelor within 7 days prior to randomization
• Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve)
• Contraindication that ticagrelor or clopidogrel should not be administered Patient requires dialysis
• History of intolerance or allergy to aspirin